{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:36:27Z","timestamp":1767857787650,"version":"3.49.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Guangzhou Key Medical Discipline Construction Project","award":["2017"],"award-info":[{"award-number":["2017"]}]},{"name":"Guangdong Science and Technology Plan Project","award":["20160918"],"award-info":[{"award-number":["20160918"]}]},{"name":"Guangzhou Science Technology and Innovation Commission","award":["2014Y2-00152"],"award-info":[{"award-number":["2014Y2-00152"]}]},{"name":"Guangzhou Science Technology and Innovation Commission","award":["2014Y2-00548"],"award-info":[{"award-number":["2014Y2-00548"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>The efficacy of different timings of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in controlling malignant ascites caused by peritoneal carcinomatosis of colorectal cancer (CRC) is not well defined. The study aims to investigate the clinical efficacy and safety of different timings of CRS with HIPEC for malignant ascites caused by peritoneal carcinomatosis from CRC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>This was a preliminary randomized controlled study performed at the Intracelom Hyperthermic Perfusion Therapy Center of the Cancer Hospital of Guangzhou Medical University (China) from December 2008 to December 2016. The patients were randomized to: CRS, followed by HIPEC (CRS+HIPEC; n\u200a=\u200a14), and ultrasound-guided HIPEC, followed by CRS 1 to 2 weeks later (HIPEC+ delayed cytoreductive surgery (dCRS) group, n\u200a=\u200a14). The endpoints were complete remission rate of ascites, successful complete CRS rate, and overall survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Malignant ascites in all patients showed complete remission; the total effective rate was 100%. Complete CRS was not feasible in any patient. The median follow-up of the 2 groups was 41.9 and 42.3 months in the CRS+HIPEC and HIPEC+dCRS groups, respectively. Overall survival was 14.5 (95%CI: 7\u201319 months) and 14.3 months (95%CI: 4\u201321 months) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&gt;\u200a.05). The adverse effects of HIPEC were manageable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>CRS+HIPEC and HIPEC+dCRS have the same efficacy in controlling malignant ascites caused by CRC and peritoneal carcinomatosis. The timing of CRS and HIPEC does not prolong the survival of patients with peritoneal carcinomatosis from CRC, even when a complete CRS is not feasible.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021546","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T06:12:55Z","timestamp":1597299175000},"page":"e21546","source":"Crossref","is-referenced-by-count":14,"title":["Cytoreductive surgery and HIPEC for malignant ascites from colorectal cancer - a randomized study"],"prefix":"10.1097","volume":"99","author":[{"given":"Mingchen","family":"Ba","sequence":"first","affiliation":[{"name":"Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangzhou Dermatology Institute, Guangzhou, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfeng","family":"Gong","sequence":"additional","affiliation":[{"name":"Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinbin","family":"Wu","sequence":"additional","affiliation":[{"name":"Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunpeng","family":"Lin","sequence":"additional","affiliation":[{"name":"Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinuo","family":"Tu","sequence":"additional","affiliation":[{"name":"Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanbo","family":"Wu","sequence":"additional","affiliation":[{"name":"Intracelom Hyperthermic Perfusion Therapy Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","article-title":"Malignant ascites: pathophysiology and treatment","volume":"18","author":"Cavazzoni","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3892\/ol.2017.6342","article-title":"Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites","volume":"14","author":"Ni","year":"2017","journal-title":"Oncol Lett"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000338070","article-title":"Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites?","volume":"6","author":"de Mestier","year":"2012","journal-title":"Case Rep Gastroenterol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejso.2007.05.015","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer","volume":"34","author":"Facchiano","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ejso.2006.03.014","article-title":"Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites","volume":"32","author":"Garofalo","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","article-title":"Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients","volume":"100","author":"Valle","year":"2009","journal-title":"J Surg Oncol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijsu.2015.09.074","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery","volume":"23","author":"Valle","year":"2015","journal-title":"Int J Surg"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00432-014-1692-5","article-title":"Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites","volume":"140","author":"Ba","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3748\/wjg.v16.i15.1901","article-title":"Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites","volume":"16","author":"Ba","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00464-013-2800-3","article-title":"Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites","volume":"27","author":"Ba","year":"2013","journal-title":"Surg Endosc"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3892\/or.2012.1913","article-title":"B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites","volume":"28","author":"Cui","year":"2012","journal-title":"Oncol Rep"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1245\/s10434-009-0774-0","article-title":"Malignant ascites symptom cluster in patients referred for paracentesis","volume":"17","author":"Husain","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","article-title":"Malignant ascites: past, present, and future","volume":"198","author":"Adam","year":"2004","journal-title":"J Am Coll Surg"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02987754","article-title":"Treatment of malignant peritoneal effusion in digestive and ovarian cancer","volume":"9","author":"Gilly","year":"1992","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1245\/s10434-007-9635-x","article-title":"Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs","volume":"15","author":"Benoit","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10434-004-1167-z","article-title":"Long-term survival of peritoneal carcinomatosis of colorectal origin","volume":"12","author":"Verwaal","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3748\/wjg.14.1159","article-title":"Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis","volume":"14","author":"Al-Shammaa","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9","article-title":"Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy","volume":"92","author":"Elias","year":"2001","journal-title":"Cancer"},{"key":"R20-20230915","first-page":"143","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future","volume":"7","author":"Dehal","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3748\/wjg.15.756","article-title":"Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis","volume":"15","author":"Huh","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1245\/s10434-007-9678-z","article-title":"Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin","volume":"15","author":"McQuellon","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1245\/s10434-007-9648-5","article-title":"Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis","volume":"15","author":"Ceelen","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00595-016-1335-3","article-title":"Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin","volume":"46","author":"Cravioto-Villanueva","year":"2016","journal-title":"Surg Today"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/jso.24169","article-title":"Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study","volume":"113","author":"Simkens","year":"2016","journal-title":"J Surg Oncol"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s13193-016-0499-z","article-title":"Cytoreductive surgery plus HIPEC for peritoneal metastases from colorectal cancer","volume":"7","author":"Bhatt","year":"2016","journal-title":"Indian J Surg Oncol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1245\/s10434-016-5211-6","article-title":"Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC","volume":"23","author":"Simkens","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1245\/s10434-016-5203-6","article-title":"Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"23","author":"Chia","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0959-8049(01)00058-2","article-title":"Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin","volume":"37","author":"Witkamp","year":"2001","journal-title":"Eur J Cancer"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1245\/s10434-016-5096-4","article-title":"Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin in the era of value-based medicine","volume":"23","author":"Vanounou","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R32-20230915","first-page":"3","article-title":"Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"7","author":"Cummins","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/SLA.0000000000001593","article-title":"Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis","volume":"263","author":"Kwakman","year":"2016","journal-title":"Ann Surg"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ejso.2008.10.006","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival","volume":"35","author":"Hagendoorn","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00268-005-0486-y","article-title":"Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer","volume":"30","author":"Zanon","year":"2006","journal-title":"World J Surg"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1245\/s10434-013-3224-y","article-title":"Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites","volume":"21","author":"Randle","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1245\/s10434-006-9185-7","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. society of surgical oncology","volume":"14","author":"Esquivel","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/ejso.2000.1038","article-title":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome","volume":"27","author":"Sugarbaker","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jamcollsurg.2006.12.048","article-title":"Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures","volume":"204","author":"Levine","year":"2007","journal-title":"J Am Coll Surg"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J Clin Oncol"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13193-016-0504-6","article-title":"Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases","volume":"7","author":"Mehta","year":"2016","journal-title":"Indian J Surg Oncol"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00268-006-0038-0","article-title":"Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity","volume":"30","author":"Roviello","year":"2006","journal-title":"World J Surg"},{"key":"R44-20230915","first-page":"72","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection","volume":"7","author":"Esquivel","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jso.21083","article-title":"Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer","volume":"98","author":"Helm","year":"2008","journal-title":"J Surg Oncol"},{"key":"R46-20230915","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ejso.2007.12.003","article-title":"Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience","volume":"34","author":"Scaringi","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"R47-20230915","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.3747\/co.23.2831","article-title":"Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives","volume":"23","author":"Spiliotis","year":"2016","journal-title":"Curr Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:16:59Z","timestamp":1694827019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":47,"journal-issue":{"issue":"33","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021546","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]}}}